中国普外基础与临床杂志

中国普外基础与临床杂志

人精子蛋白 17 在乳腺癌中的研究现状

查看全文

目的 总结人精子蛋白 17 (sperm protein 17,SP17)在乳腺癌中的研究现状。 方法 在 PubMed、Web of Science、CNKI、万方等数据库中检索 SP17 在乳腺癌中的表达情况及其功能的研究,并对其结果进行综述。 结果 目前研究发现 SP17 只在乳腺癌组织中表达,而在正常乳腺组织中不表达。有研究检测到 SP17 只在转移阶段的肿瘤细胞中被检测到;同时体外研究发现,SP17 阳性表达的乳腺癌细胞可以被特异性 T 淋巴细胞杀死。 结论 SP17 具有成为乳腺癌免疫治疗新靶点的潜能,可能具有促进癌细胞迁移的作用,未来仍需更多研究证实其在乳腺癌发生及发展过程中的作用,进而加速 SP17 疫苗的研制及其在乳腺癌临床治疗中的应用。

Objective To summarize current research status of sperm protein 17 (SP17) in breast cancer. Method Bysearching PubMed, Web of Science, CNKI, and Wanfang databases, the studies about expression and function of SP17 in the breast cancer were summarized. Results SP17 only expressed in the breast cancer tissue but not in the normal breast tissue. The result of the study showed that SP17 was only detected in the metastatic stage of tumor cells. The preclinical trails found that the breast cancer cells with SP17 positive expression could be killed by the specific T lymphocyte. Conclusions SP17 might be a potential target of immunotherapy of breast cancer, it might promote metastasis of cancer. More studies are needed to further explore its function in tumor development, thus accelerate its application in clinical practice.

关键词: 人精子蛋白 17; 乳腺癌; 免疫治疗; 功能

Key words: sperm protein 17; breast cancer; immunotherapy; function

引用本文: 周宇婷, 谭秋雯, 邱娟娟, 吕青. 人精子蛋白 17 在乳腺癌中的研究现状. 中国普外基础与临床杂志, 2018, 25(2): 242-244. doi: 10.7507/1007-9424.201706143 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2. Chen S, Gu F, Li K, et al. A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro. J Hematol Oncol, 2017, 10(1): 63.
3. Sunay MM, Foote JB, Leatherman JM, et al. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol, 2017, 46: 112-123.
4. Salmaninejad A, Zamani MR, Pourvahedi M, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest, 2016, 45(7): 619-640.
5. Li Y, Li J, Wang Y, et al. Roles of cancer/testis antigens (CTAs) in breast cancer. Cancer Lett, 2017, 399: 64-73.
6. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun, 2004, 4: 1.
7. Grigoriadis A, Caballero OL, Hoek KS, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA, 2009, 106(32): 13493-13498.
8. Chen YT, Ross DS, Chiu R, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One, 2011, 6(3): e17876.
9. Dong G, Loukinova E, Smith CW, et al. Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem Suppl, 1997, 28-29: 90-100.
10. Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood, 2002, 100(3): 961-965.
11. Grizzi F, Gaetani P, Franceschini B, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer, 2006, 6: 23.
12. Mirandola L, Figueroa JA, Phan TT, et al. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget, 2015, 6(5): 2812-2826.
13. Xiang SD, Gao Q, Wilson KL, et al. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine. Vaccine, 2015, 33(44): 5950-5959.
14. Li FQ, Liu Q, Han YL, et al. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer, 2010, 10: 429.
15. Pandey A, Kurup A, Shrivastava A, et al. Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol, 2012, 31(5): 302-320.
16. Wen Y, Richardson RT, Widgren EE, et al. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J, 2001, 357(Pt 1): 25-31.
17. Lea IA, Widgren EE, O’Rand MG. Association of sperm protein 17 with A-kinase anchoring protein 3 in flagella. Reprod Biol Endocrinol, 2004, 2: 57.
18. Grizzi F, Franceschini B, Di Biccari S, et al. Sperm protein 17 and AKAP-associated sperm protein cancer/testis antigens are expressed in ciliated hepatic foregut cysts. Histopathology, 2015, 67(3): 398-403.
19. Arnaboldi F, Menon A, Menegola E, et al. Sperm protein 17 is an oncofetal antigen: a lesson from a murine model. Int Rev Immunol, 2014, 33(5): 367-374.
20. Li FQ, Han YL, Liu Q, et al. Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. BMC Cancer, 2009, 9: 323.
21. Shang B, Gao A, Pan Y, et al. CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell Death Dis, 2014, 5: e1285.
22. Song ZB, Ni JS, Wu P, et al. Testes-specific protease 50 promotes cell invasion and metastasis by increasing NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Death Dis, 2015, 6: e1703.
23. Yang F, Zhou X, Miao X, et al. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat, 2014, 145(1): 23-32.
24. Maine EA, Westcott JM, Prechtl AM, et al. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget, 2016, 7(12): 14708-14726.
25. Chiriva-Internati M, Ferrari R, Yu YF, et al. Sperm protein 17 is expressed in primary and metastatic breast cancer. FASEB J, 2008, 22 (Meeting Abstract Supplement): 1079.21.
26. Gjerstorff MF, Ditzel HJ. Limited SP17 expression within tumors diminishes its therapeutic potential. Tissue Antigens, 2012, 80(6): 523-527.
27. Song JX, Cao WL, Li FQ, et al. Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells. Med Oncol, 2012, 29(4): 2923-2931.
28. Chiriva-Internati M, Yu Y, Mirandola L, et al. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One, 2010, 5(5): e10471.
29. Xiang SD, Gao Q, Wilson KL, et al. A nanoparticle based Sp17 peptide vaccine exposes new immuno-dominant and species cross-reactive B cell epitopes. Vaccines (Basel), 2015, 3(4): 875-893.